Abivax sets May 11, 2026 shareholder meeting
Abivax SA has scheduled its annual ordinary and extraordinary general meeting for May 11, 2026, at 3:00 pm CEST in Paris.
Rhea-AI Filing Summary
Abivax SA has scheduled its annual ordinary and extraordinary general meeting for May 11, 2026, at 3:00 pm CEST in Paris. The company states that the agenda, draft resolutions and details on how to attend and vote were published in the French official legal bulletin on April 3, 2026. Preparatory documents required under French law are available to shareholders through the company’s website. This report and the attached press release are also incorporated by reference into Abivax’s existing Form F-3 and Form S-8 registration statements in the United States.
Positive
- None.
Negative
- None.
Key Figures
General meeting date: May 11, 2026
Meeting time: 3:00 pm CEST
BALO notice date: April 3, 2026
3 metrics
General meeting date
May 11, 2026
Annual ordinary and extraordinary general meeting
Meeting time
3:00 pm CEST
Scheduled start time of the general meeting
BALO notice date
April 3, 2026
Publication date of preliminary notice and draft resolutions
Key Terms
ordinary and extraordinary general meeting, Bulletin des Annonces Légales Obligatoires (BALO), Article R.22-10-23 of the French Commercial Code, Phase 3 clinical trials, +1 more
5 terms
ordinary and extraordinary general meeting financial
"informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held"
Bulletin des Annonces Légales Obligatoires (BALO) regulatory
"was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026"
Article R.22-10-23 of the French Commercial Code regulatory
"The documents referred to in Article R.22-10-23 of the French Commercial Code are available"
Phase 3 clinical trials medical
"obefazimod (ABX464), is in Phase 3 clinical trials for the treatment"
Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.
ulcerative colitis medical
"Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis"
A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Abivax (ABVX) hold its 2026 annual general meeting?
Abivax will hold its annual ordinary and extraordinary general meeting on May 11, 2026, at 3:00 pm CEST. The meeting will take place at the Paris Marriott Opera Ambassador hotel, 16 boulevard Haussmann, in Paris, France, for all eligible shareholders.
What information about the Abivax (ABVX) general meeting was published in BALO?
Abivax explains that the preliminary notice of meeting, including the agenda, draft resolutions, and details on attending and voting, was published in the Bulletin des Annonces Légales Obligatoires on April 3, 2026, under number 2600756 as part of standard French legal requirements.
How does this Abivax (ABVX) 6-K relate to its U.S. registration statements?
Abivax indicates that this Form 6-K, including the attached press release, is incorporated by reference into its Form F-3 and Form S-8 registration statements. This means the meeting-related information becomes part of those U.S. securities registration documents from the filing date.
What business focus does Abivax (ABVX) highlight in this communication?
Abivax describes itself as a clinical-stage biotechnology company developing therapies that harness natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod (ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis.
Who is the investor relations contact for Abivax (ABVX) regarding the 2026 general meeting?
Abivax lists Patrick Malloy as SVP, Investor Relations, with email patrick.malloy@abivax.com and phone +1 847 987 4878. Shareholders can use these contact details for questions related to the general meeting or broader investor information about the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
